Abstract

Microrchidia family CW-type zinc finger 2 (MORC2) is a ubiquitously expressed protein that contributes to chromatin remodeling, DNA repair, and lipogenesis. However, its role in cholangiocarcinoma (CCA) remains largely unknown. The aim of this study was to investigate the expression profile of MORC2 and its potential functions in CCA progression. The results showed that MORC2 was upregulated in human CCA specimens and cell lines. MORC2 expression was significantly associated with serum CA19-9 levels (P = 0.009), TNM stage (P = 0.003) and lymph node invasion (P = 0.004). Furthermore, high MORC2 expression was associated with poor 5-year survival (P = 0.016). Functional experiments revealed that MORC2 knockdown could suppress CCA cell proliferation, migration, and invasion both in vivo and in vitro. Mechanically, we found that MORC2 promoted CCA cell metastasis through the EMT process and enhanced proliferation via the Akt signaling pathway. Moreover, MORC2 was negatively regulated by miR-186-5p. MiR-186-5p could influence CCA cell proliferation, migration and metastasis by regulating MORC2. Taken together, the findings of this study demonstrated the oncogenic role of MORC2 in CCA tumorigenesis and metastasis, and clarified an underlying regulatory mechanism mediating MORC2 upregulation, which may provide a novel therapeutic target in CCA treatment.

Highlights

  • Cholangiocarcinoma (CCA) is a highly aggressive cancer derived from bile duct epithelial cells

  • Microrchidia family CW-type zinc finger 2 (MORC2) expression was significantly associated with serum CA19-9 levels (P = 0.009), TNM stage (P = 0.003) and lymph node invasion (P = 0.004)

  • The results revealed that the mRNA levels of MORC2 were markedly upregulated in CCA cells compared to those in the human intrahepatic biliary epithelial cell line (HIBEC) (Figure 1F)

Read more

Summary

Introduction

Cholangiocarcinoma (CCA) is a highly aggressive cancer derived from bile duct epithelial cells. Several reports have shown that the incidence and mortality of CCA is increasing worldwide [1]. Surgical resection remains the most effective treatment for CCA patients. Most patients present with advanced disease, providing few chances for surgery. The poor understanding of the molecular mechanism underlying CCA tumorigenesis impedes the development of new agents. Identifying novel targets is extremely essential to improving the survival of patients with CCA

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call